Literature DB >> 9927043

A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity.

N Suh1, Y Wang, T Honda, G W Gribble, E Dmitrovsky, W F Hickey, R A Maue, A E Place, D M Porter, M J Spinella, C R Williams, G Wu, A J Dannenberg, K C Flanders, J J Letterio, D J Mangelsdorf, C F Nathan, L Nguyen, W W Porter, R F Ren, A B Roberts, N S Roche, K Subbaramaiah, M B Sporn.   

Abstract

The new synthetic oleanane triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) is a potent, multifunctional molecule. It induces monocytic differentiation of human myeloid leukemia cells and adipogenic differentiation of mouse 3T3-L1 fibroblasts and enhances the neuronal differentiation of rat PC12 pheochromocytoma cells caused by nerve growth factor. CDDO inhibits proliferation of many human tumor cell lines, including those derived from estrogen receptor-positive and -negative breast carcinomas, myeloid leukemias, and several carcinomas bearing a Smad4 mutation. Furthermore, it suppresses the abilities of various inflammatory cytokines, such as IFN-gamma, interleukin-1, and tumor necrosis factor-alpha, to induce de novo formation of the enzymes inducible nitric oxide synthase (iNos) and inducible cyclooxygenase (COX-2) in mouse peritoneal macrophages, rat brain microglia, and human colon fibroblasts. CDDO will also protect rat brain hippocampal neurons from cell death induced by beta-amyloid. The above activities have been found at concentrations ranging from 10(-6) to 10(-9) M in cell culture, and these results suggest that CDDO needs further study in vivo, for either chemoprevention or chemotherapy of malignancy as well as for neuroprotection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9927043

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  90 in total

1.  Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives.

Authors:  Nisha R Parikh; Animesh Mandal; Deepak Bhatia; Kodappully Sivaraman Siveen; Gautam Sethi; Anupam Bishayee
Journal:  Phytochem Rev       Date:  2014-12       Impact factor: 5.374

2.  Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia.

Authors:  Twee Tsao; Steven Kornblau; Stephen Safe; Julie C Watt; Vivian Ruvolo; Wenjing Chen; Yihua Qiu; Kevin R Coombes; Zhenlin Ju; Maen Abdelrahim; Wendy Schober; Xiaoyang Ling; Dimitris Kardassis; Colin Meyer; Aaron Schimmer; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

3.  CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha.

Authors:  Steffen Koschmieder; Francesco D'Alò; Hanna Radomska; Christine Schöneich; Ji Suk Chang; Marina Konopleva; Susumu Kobayashi; Elena Levantini; Nanjoo Suh; Annalisa Di Ruscio; Maria Teresa Voso; Julie C Watt; Ramasamy Santhanam; Bülent Sargin; Hagop Kantarjian; Michael Andreeff; Michael B Sporn; Danilo Perrotti; Wolfgang E Berdel; Carsten Müller-Tidow; Hubert Serve; Daniel G Tenen
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

4.  The triterpenoid CDDO-Me delays murine acute graft-versus-host disease with the preservation of graft-versus-tumor effects after allogeneic bone marrow transplantation.

Authors:  Minghui Li; Kai Sun; Doug Redelman; Lisbeth A Welniak; William J Murphy
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-23       Impact factor: 5.742

Review 5.  Chemotherapeutic approaches for targeting cell death pathways.

Authors:  M Stacey Ricci; Wei-Xing Zong
Journal:  Oncologist       Date:  2006-04

Review 6.  Induction of apoptosis in lymphoid and myeloid leukemia.

Authors:  Aaron D Schimmer
Journal:  Curr Oncol Rep       Date:  2006-11       Impact factor: 5.075

7.  Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism.

Authors:  Chunyan Yang; Seung-Hee Jo; Balazs Csernus; Elizabeth Hyjek; Yifang Liu; Amy Chadburn; Y Lynn Wang
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

8.  Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer.

Authors:  Karen T Liby
Journal:  Dose Response       Date:  2013-08-01       Impact factor: 2.658

9.  Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules.

Authors:  Keith C Olsen; Amali P Epa; Ajit A Kulkarni; R Matthew Kottmann; Claire E McCarthy; Gail V Johnson; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

Review 10.  Novel pituitary ligands: peroxisome proliferator activating receptor-gamma.

Authors:  Anthony P Heaney
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.